Four Out of Five People Aware of Russia's Sputnik V Vaccine Ready to Use It, Poll Shows
MOSCOW (Sputnik) - The survey was conducted on 9-19 October and included over 12,000 respondents from 11 countries.
Four Out of Five People Aware of Russia's Sputnik V Vaccine Ready to Use It, Poll Shows
MOSCOW (Sputnik) - The survey was conducted on 9-19 October and included over 12,000 respondents from 11 countries.
Four Out of Five People Aware of Russia's Sputnik V Vaccine Ready to Use It, Poll Shows
MOSCOW (Sputnik) - The survey was conducted on 9-19 October and included over 12,000 respondents from 11 countries.
Four Out of Five People Aware of Russia's Sputnik V Vaccine Ready to Use It, Poll Shows
MOSCOW (Sputnik) - The survey was conducted on 9-19 October and included over 12,000 respondents from 11 countries.
Four Out of Five People Aware of Russia's Sputnik V Vaccine Ready to Use It, Poll Shows
MOSCOW (Sputnik) - The survey was conducted on 9-19 October and included over 12,000 respondents from 11 countries.
Four Out of Five People Aware of Russia's Sputnik V Vaccine Ready to Use It, Poll Shows
MOSCOW (Sputnik) - The survey was conducted on 9-19 October and included over 12,000 respondents from 11 countries.
Four Out of Five People Aware of Russia's Sputnik V Vaccine Ready to Use It, Poll Shows
MOSCOW (Sputnik) - The survey was conducted on 9-19 October and included over 12,000 respondents from 11 countries.
Four Out of Five People Aware of Russia's Sputnik V Vaccine Ready to Use It, Poll Shows
MOSCOW (Sputnik) - The survey was conducted on 9-19 October and included over 12,000 respondents from 11 countries.
Russia's EpiVacCorona Vaccine Is in Phase III Post-Registration Trials
MOSCOW (Sputnik) - The EpiVacCorona vaccine against COVID-19, developed by Russian research center Vector, is now in Phase III post-registration clinical trials, the head of the federal public h
Russia's EpiVacCorona Vaccine Is in Phase III Post-Registration Trials
MOSCOW (Sputnik) - The EpiVacCorona vaccine against COVID-19, developed by Russian research center Vector, is now in Phase III post-registration clinical trials, the head of the federal public h
